Veeva(VEEV)
icon
搜索文档
After Plunging -11.74% in 4 Weeks, Here's Why the Trend Might Reverse for Veeva (VEEV)
Zacks Investment Research· 2024-04-16 22:35
A downtrend has been apparent in Veeva Systems (VEEV) lately with too much selling pressure. The stock has declined 11.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, fo ...
Veeva Systems (VEEV) Ascends But Remains Behind Market: Some Facts to Note
Zacks Investment Research· 2024-04-12 06:56
The latest trading session saw Veeva Systems (VEEV) ending at $211.19, denoting a +0.13% adjustment from its last day's close. This change lagged the S&P 500's 0.74% gain on the day. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq gained 1.68%. The provider of cloud-based software services for the life sciences industry's shares have seen a decrease of 10.17% over the last month, not keeping up with the Computer and Technology sector's gain of 0.95% and the S&P 500's gain of 0.8%. The invest ...
Brokers Suggest Investing in Veeva (VEEV): Read This Before Placing a Bet
Zacks Investment Research· 2024-04-10 22:36
经纪推荐与股票评级 - 投资者通常依赖华尔街分析师的推荐来决定是否买入、卖出或持有股票[1] - Veeva Systems目前的平均经纪推荐(ABR)为1.80,介于强烈买入和买入之间[2] - 经纪推荐往往存在强烈的正向偏见,因为他们对所覆盖股票的利益[5] Zacks Rank与盈利预期 - Zacks Rank是一种有效的股票评级工具,可以有效预测股票未来的价格表现[7] - 经纪推荐和Zacks Rank是两种完全不同的衡量标准,前者基于经纪推荐,后者基于盈利预期修订[8] - 经纪推荐不一定是最新的,而Zacks Rank则会及时反映公司业务趋势的变化[13] Veeva Systems的盈利预期 - Veeva的盈利预期修订表现良好,Zacks Consensus Estimate为当前年度增长了5.3%至6.14美元[14] - 分析师对公司盈利前景的乐观态度,以及盈利预期修订的一致性,可能是股票在短期内飙升的合理原因[15] - Veeva的Zacks Rank为1(强烈买入),这与盈利预期修订的变化有关[16]
Veeva Systems (VEEV) Makes Change to Front Office (revised)
Zacks Investment Research· 2024-04-04 06:31
Veeva Systems’ (VEEV) shares lost 6.1% on Apr 2, following the mutually agreed-to announcement of the company’s CFO Brent Bowman's departure. Bowman's departure, though unexpected, is not linked to any misconduct or financial disagreements. He will continue to work as an employee of VEEV for three months to aid in the transition. Tim Cabral, a former CFO of Veeva Systems, will step in as interim CFO until a permanent replacement is found. Additionally, the company announced other changes in its executive te ...
Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop
Zacks Investment Research· 2024-04-03 22:10
Veeva Systems’ (VEEV) shares lost 6.1% on Apr 2, following the sudden announcement of the company’s CFO Brent Bowman's resignation. Bowman's departure, though unexpected, is not linked to any misconduct or financial disagreements. He will continue to work as an employee of VEEV for three months to aid in the transition. Tim Cabral, a former CFO of Veeva Systems, will step in as interim CFO until a permanent replacement is found. Additionally, the company announced other changes in its executive team, includ ...
Veeva Vault CRM Now Available for All New Customers
Prnewswire· 2024-04-01 21:03
Veeva Systems - Veeva Systems宣布早期采用者已经在美国和欧洲成功使用Vault CRM[1] - 现有Veeva CRM客户向Vault CRM的迁移预计将于2025年初开始,大多数预计将在2026年和2027年开始[1] - Vault CRM是Veeva商业云的一部分,公司可以在波士顿的Veeva商业峰会上了解更多关于Vault CRM的信息[2] - Veeva是生命科学行业的全球领导者,致力于创新、产品卓越和客户成功,为1000多家客户提供服务[3] - Veeva在一份声明中提到了关于产品和服务的前瞻性声明,强调实际结果可能与声明中提供的不同[4]
Veeva: Clinical Trial Platform Monopoly With Huge Untapped Opportunities
Seeking Alpha· 2024-03-31 14:02
JHVEPhoto Since I presented my ‘Strong Buy’ thesis for Veeva Systems (NYSE:VEEV) in June 2023, their stock price has surged by 21%. I discussed their data analytics and AI capabilities in the healthcare industry. They guide 15.5% revenue growth and 27% adjusted operating income growth for FY25. Veeva clinical platform connects clinical operations and data management, supporting healthcare customers in navigating trial collaborations. I think it is an untapped market and could generate long-term growth for V ...
Veeva(VEEV) - 2024 Q4 - Annual Report
2024-03-26 04:06
公司概况 - Veeva是全球生命科学行业领先的行业云解决方案提供商[14] - 公司的目标是成为生命科学行业最具战略性的技术合作伙伴,通过支持研发和商业功能,实现长期领导地位[16] 产品与服务 - Veeva的行业云解决方案涵盖三大产品类别,分别是Veeva Development Cloud、Veeva Commercial Cloud和Veeva Data Cloud,旨在满足制药、生物技术和医疗器械和诊断(MedTech)公司在商业和研发运营中最紧迫的战略需求[19] - Veeva Development Cloud包括为生命科学公司的临床、监管、质量和安全功能提供的应用套件,所有这些都建立在公司专有的Veeva Vault平台上[20] - Veeva商业云包括销售、营销和医务部门的解决方案[30] - Veeva Data Cloud是现代数据平台,包括连接的参考数据、深度数据和交易数据[34] 技术基础 - 公司的技术基本上基于多租户架构,为所有使用我们解决方案的客户应用共同的一致管理实践[52] - 公司的基础设施提供商采用先进措施确保物理完整性和安全性,包括冗余电源和冷却系统、防火和防洪机制、持续的安全覆盖、入口处生物识别读卡器和匿名外部[51] 知识产权 - 截至2024年1月31日,公司拥有74项美国专利和13项国际专利[63] - 公司拥有90项美国和国际专利申请[63]
Veeva Vault EDC Surpasses 1,000 Study Start Milestone
Prnewswire· 2024-03-20 19:03
Eight of the top 20 biopharmas standardize on Vault EDC to build a modern clinical data foundation BARCELONA, Spain, March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts. The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC. This underscores the ongoing shift to a ...
Veeva (VEEV) Upgraded to Strong Buy: Here's What You Should Know
Zacks Investment Research· 2024-03-20 01:01
Investors might want to bet on Veeva Systems (VEEV) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Individual inv ...